VeracyteVCYT
About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Employees: 824
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,042% more call options, than puts
Call options by funds: $8.4M | Put options by funds: $736K
116% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 25
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
17% more capital invested
Capital invested by funds: $2.78B [Q3] → $3.25B (+$471M) [Q4]
8% more funds holding
Funds holding: 290 [Q3] → 314 (+24) [Q4]
0.52% more ownership
Funds ownership: 106.74% [Q3] → 107.26% (+0.52%) [Q4]
14% less repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 119
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Guggenheim Subbu Nambi 33% 1-year accuracy 7 / 21 met price target | 21%upside $37 | Buy Maintained | 9 Apr 2025 |
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target | 48%upside $45 | Overweight Reiterated | 26 Mar 2025 |
Craig-Hallum John Wilkin 33% 1-year accuracy 1 / 3 met price target | 48%upside $45 | Buy Initiated | 20 Mar 2025 |
UBS Lu Li 0% 1-year accuracy 0 / 3 met price target | 61%upside $49 | Buy Maintained | 25 Feb 2025 |
Needham Mike Matson 37% 1-year accuracy 44 / 120 met price target | 67%upside $51 | Buy Reiterated | 25 Feb 2025 |
Financial journalist opinion
Based on 9 articles about VCYT published over the past 30 days
